癌症（英文版）2012，Vol.31Issue(2)：100-109,10.DOI:10.5732/cjc.011.10326
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology
摘要
Abstract
Multidrug resistance (MDR),which significantly decreases the efficacy of anticancer drugs and causes tumor recurrence,has been a major challenge in clinical cancer treatment with chemotherapeutic drugs for decades.Several mechanisms of overcoming drug resistance have been postulated.Well known Pglycoprotein (P-gp) and other drug efflux transporters are considered to be critical in pumping anticancer drugs out of cells and causing chemotherapy failure.Innovative theranostic (therapeutic and diagnostic)strategies with nanoparticles are rapidly evolving and are anticipated to offer opportunities to overcome these limits.In this review,we discuss the mechanisms of drug efflux-mediated resistance and the application of multiple nanoparticle-based platforms to overcome chemoresistance and improve therapeutic outcome.关键词
multidrug resistance/drug efflux transporter/cancer nanotechnologyKey words
multidrug resistance/drug efflux transporter/cancer nanotechnology引用本文复制引用
Xue Xue,Xing-Jie Liang..Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology[J].癌症（英文版）,2012,31(2):100-109,10.基金项目
This work is financially supported by the National Key Basic Research Program of China (973 projects 2009CB930200) and the program of National Natural Science Foundation of China (30970784 and 81171455).The authors are grateful for the support of the Chinese Academy of Sciences (CAS) "Hundred Talents Program" and CAS Knowledge Innovation Program. （973 projects 2009CB930200）
